Stem cell-derived vaccines represent an innovative frontier in vaccine development, utilizing stem cells to generate immune components necessary for immune response. Stem cells, particularly pluripotent stem cells, can be manipulated to produce various immune-related proteins, cells, or even entire vaccine platforms. These vaccines offer several advantages, including the ability to generate large quantities of antigens or immunologically active components for use in vaccine formulations. Additionally, stem cell-derived vaccines can be tailored to target specific pathogens with a higher degree of precision, potentially improving the effectiveness and safety profile of vaccines. This approach is particularly promising for creating vaccines against complex diseases, such as cancer or autoimmune disorders, where conventional vaccine strategies may be less effective. Ongoing research into stem cell-derived vaccines aims to explore their potential in combating a wide range of infectious diseases and even chronic conditions, offering a new dimension to vaccine development.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey